DFN-11 Injection in Episodic Migraine With or Without Aura

Trial Profile

DFN-11 Injection in Episodic Migraine With or Without Aura

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs DFN 11 (Primary)
  • Indications Migraine with aura; Migraine without aura
  • Focus Therapeutic Use
  • Acronyms RESTOR
  • Sponsors Dr Reddys Laboratories
  • Most Recent Events

    • 15 Nov 2017 Results published in a Promius Pharma Media Release
    • 15 Nov 2017 According to a Promius Pharma media release, Primary endpoint and other endpoint (pain freedom at 1 hour postdose) has been met.
    • 15 Nov 2017 Primary endpoint has been met. (The proportion of subjects who are pain free at 2 hours after dosing as reported by the subject in the eDiary), according to a Promius Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top